Boehringer Ingelheim

This study tests a new drug, BI 3923948, in people with advanced solid tumors that have spread and are hard to treat. About 60 adults will receive the drug alone or with an immunotherapy (checkpoint inhibitor) to find the safest dose and see if it shrinks tumors. The drug is inje…

This study tests an experimental oral drug, BI 3000202, in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of the drug or a placebo, taken daily for a year alongside their usual lupus treatments. The g…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior therapy. Participants take one pill daily and are grouped by cancer type and HER2 alteration. The trial aims to see if …

This study tests an experimental tablet (BI 764198) for people with focal segmental glomerulosclerosis (FSGS), a kidney condition that can lead to kidney failure. About 286 adults and teens will take either the drug or a placebo once daily for up to 2 years, while continuing thei…

This study looks at the long-term safety of a daily pill called nerandomilast for people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Participants must have completed a previous study with this drug. The goal is to see if the medicine is safe …

This study tests whether combining three different medicines can shrink tumors in adults with head and neck cancer that has spread or come back. Participants are split into three groups, each receiving a different mix of the drugs as infusions. The goal is to see if the combinati…

This study tests a new oral drug, zongertinib, that blocks HER2 — a protein that fuels cancer growth. It is for adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and no longer responds to standard treatments. The trial first finds the best dose of z…

This early-stage study tests a new drug called BI 3810944 in adults with advanced solid tumors or melanoma who have run out of treatment options. The main goals are to find safe doses and see if the drug can shrink tumors. Participants receive the drug every three weeks, with wee…

This study tests whether adding vicadrostat to the standard heart failure medicine empagliflozin helps people with heart failure live longer and avoid hospital stays. About 6000 adults with heart failure symptoms and a preserved pumping function (LVEF 40% or higher) will be rando…

This study tests an experimental tablet called nerandomilast for people with lung scarring (fibrosis) linked to autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults whose lung function hasn't improved with standard treatment will take the drug or a place…

This early-stage study tests a new drug, BI 764532, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The main goal is to find the high…

This early-stage study is testing an experimental drug called BI 3031185 in healthy men aged 18 to 50. The main goal is to see if the drug is safe and how the body processes it. Participants will take multiple doses of the drug or a placebo. This study does not aim to treat any d…

This study looks at how mild, moderate, and severe liver problems change the way the body processes a medicine called BI 1584862. About 44 adults, some with liver issues and some without, will take a single dose of the drug. Researchers will monitor safety and measure drug levels…

This early-stage trial tests the safety and how the body handles a new drug called BI 3804379. About 106 healthy adults aged 18 to 65 will receive either the drug or a placebo as a shot under the skin. The study aims to find any side effects and measure drug levels in the blood, …